Guardant Health, Inc. has signed an agreement with Janssen Biotech Inc. to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for amivantamab, an antibody that Janssen is developing for the treatment of non-small cell lung cancer (NSCLC).
With this strategic collaboration, the companies will work together to co-market their respective products in the US, Canada, Japan and Europe, according to Guardant. Other terms of the deal are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?